Trials / Conditions / Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

13 registered clinical trials studyying Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell T NCT07365306	City of Hope Medical Center	Phase 2
Recruiting	ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lym NCT07098364	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Recruiting	Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refracto NCT06649812	National Cancer Institute (NCI)	Phase 2
Recruiting	Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T NCT06784726	University of Washington	Phase 2
Recruiting	Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for NCT06905509	Joseph Tuscano	Phase 2
Recruiting	Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphom NCT06834373	Mayo Clinic	Phase 2
Recruiting	Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patien NCT05821088	David Bond, MD	Phase 2
Active Not Recruiting	TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lym NCT05507541	Mayo Clinic	Phase 2
Withdrawn	Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Rec NCT05228249	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymph NCT05359211	Fred Hutchinson Cancer Center	Phase 1
Active Not Recruiting	Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin NCT05202782	Northwestern University	Phase 2
Terminated	CD19-Specific T Cells Post AlloSCT NCT03579888	M.D. Anderson Cancer Center	Phase 1
Terminated	huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Ac NCT03103971	Fred Hutchinson Cancer Center	Phase 1